Our diversified pipeline is focused on our obesity, alpha-1 antitrypsin deficiency and PNPLA3 I148M liver disease programs and includes clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as several preclinical programs utilizing our versatile RNA medicines platform. Oversee clinical program quality and sponsor oversight of CROs, investigator sites, laboratories, and specialty vendors, including assessment of risks related to monitoring, protocol deviations, informed consent, investigational product accountability, blinding, and essential records.